News & Updates

Patients with cancer who have received COVID-19 booster vaccinations are better protected against severe disease, according to real-world data from four healthcare systems in the US.

Treatment with apremilast results in fat mass reduction among patients with psoriatic arthritis (PsA), indicating positive cardiovascular (CV) and metabolic effects, which may lower the risk of CV events, a recent study has shown.

Significant delays occur in the initiation of tocilizumab (TCZ) therapy among patients with giant cell arteritis (GCA), reports a US study.

New drug applications approved by US FDA as of 1-15 June 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Updated results from the phase IIIB HARMONIE trial demonstrate sustained efficacy of the long-acting monoclonal antibody nirsevimab against respiratory syncytial virus-associated lower respiratory tract infection (RSV-LRTI) hospitalization through day 181 post-dose.

Infants who contract an invasive bacterial infection during the first week of life have double the risk of epilepsy in childhood, according to a register-based cohort study from Denmark.

The addition of once-weekly semaglutide to an automated insulin delivery (AID) system leads to significantly improved time in range (TIR) and reduced body weight in adults with type 1 diabetes (T1D) and obesity compared with AID alone, according to the ADJUST-T1D* trial presented at ADA 2025. 

New drug applications approved by US FDA as of 16-30 June 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A primary care–based multicomponent intervention helps identify patients with antihypertensive medication nonadherence but does not result in improvements in adherence or blood pressure (BP), as reported in a study.